Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Net Income 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly net income history and growth rate from 2020 to 2026. Net income is the total earnings of a company after all expenses, including taxes and interest, have been deducted from total revenues.
- Inhibikase Therapeutics Inc. net income for the quarter ending March 31, 2026 was -16.4 M, a 19.75% increase year-over-year.
- Inhibikase Therapeutics Inc. net income for the twelve months ending March 31, 2026 was -51.9 M, a 159.75% increase year-over-year.
- Inhibikase Therapeutics Inc. annual net income for 2024 was -27.5 M, a 44.62% increase from 2023.
- Inhibikase Therapeutics Inc. annual net income for 2023 was -19.0 M, a 5.40% increase from 2022.
- Inhibikase Therapeutics Inc. annual net income for 2022 was -18.1 M, a 22.10% increase from 2021.
- Inhibikase Therapeutics Inc. annual net income for 2021 was -14.8 M.
Net Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Inhibikase Therapeutics Inc. Net Income — FAQ
Inhibikase Therapeutics Inc. (IKT) net income over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is Inhibikase Therapeutics Inc.'s net income?
Inhibikase Therapeutics Inc. (IKT) reported net income of -$28M for fiscal 2024.
Where can I see IKT's net income history?
The chart and table above show Inhibikase Therapeutics Inc.'s net income by year and by quarter, including the growth rate.